Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2021 from OUS - Institute for Cancer Research
27 publications found
Wetting regulates autophagy of phase-separated compartments and the cytosol
Nature
DOI 10.1038/s41586-020-2992-3, PubMed 33473217
miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer
PLoS Comput Biol, 17 (2), e1008608
DOI 10.1371/journal.pcbi.1008608, PubMed 33566819
Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy
Stem Cell Rev Rep, 17 (1), 63-70
DOI 10.1007/s12015-020-10004-x, PubMed 32696426
Uptake of circulating extracellular vesicles from rectal cancer patients and differential responses by human monocyte cultures
FEBS Open Bio (in press)
DOI 10.1002/2211-5463.13098, PubMed 33512765
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Cancer Immunol Immunother (in press)
DOI 10.1007/s00262-021-02876-w, PubMed 33580363
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women
N Engl J Med, 384 (5), 428-439
DOI 10.1056/NEJMoa1913948, PubMed 33471991
The methyltransferase METTL9 mediates pervasive 1-methylhistidine modification in mammalian proteomes
Nat Commun, 12 (1), 891
DOI 10.1038/s41467-020-20670-7, PubMed 33563959
FANCD2 modulates the mitochondrial stress response to prevent common fragile site instability
Commun Biol, 4 (1), 127
DOI 10.1038/s42003-021-01647-8, PubMed 33514811
Efficient gene expression signature for a breast cancer immuno-subtype
PLoS One, 16 (1), e0245215
DOI 10.1371/journal.pone.0245215, PubMed 33434192
Intravital microscopy of tumor vessel morphology and function using a standard fluorescence microscope
Eur J Nucl Med Mol Imaging (in press)
DOI 10.1007/s00259-021-05243-0, PubMed 33606081
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
Cancers (Basel), 13 (3)
DOI 10.3390/cancers13030499, PubMed 33525508
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Sci Adv, 7 (8)
DOI 10.1126/sciadv.abe4038, PubMed 33608276
Ebulin l Is Internalized in Cells by Both Clathrin-Dependent and -Independent Mechanisms and Does Not Require Clathrin or Dynamin for Intoxication
Toxins (Basel), 13 (2)
DOI 10.3390/toxins13020102, PubMed 33573355
In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study
Breast Cancer Res, 23 (1), 17
DOI 10.1186/s13058-021-01393-z, PubMed 33526044
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016
A global analysis of the reconstitution of PTEN function by translational readthrough of PTEN pathogenic premature termination codons
Hum Mutat (in press)
DOI 10.1002/humu.24186, PubMed 33600059
Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers
Front Immunol, 11, 576756
DOI 10.3389/fimmu.2020.576756, PubMed 33488576
Proteomic analyses Identify Major Vault Protein as a Prognostic Biomarker for Fatal Prostate Cancer
Carcinogenesis (in press)
DOI 10.1093/carcin/bgab015, PubMed 33609362
The phosphatidylinositol 3-phosphate-binding protein SNX4 controls ATG9A recycling and autophagy
J Cell Sci, 134 (3)
DOI 10.1242/jcs.250670, PubMed 33468622
System-Wide Pollution of Biomedical Data: Consequence of the Search for Hub Genes of Hepatocellular Carcinoma Without Spatiotemporal Consideration
Mol Diagn Ther, 25 (1), 9-27
DOI 10.1007/s40291-020-00505-3, PubMed 33475988
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Blood Adv, 5 (1), 334-343
DOI 10.1182/bloodadvances.2020003423, PubMed 33570649
Challenges to Bringing Personalized Medicine to a Low-Resource Setting in Peru
Int J Environ Res Public Health, 18 (4)
DOI 10.3390/ijerph18041470, PubMed 33557277
Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers
Breast Cancer Res Treat
DOI 10.1007/s10549-020-06072-9, PubMed 33423179
Artificial intelligence, machine learning, and drug repurposing in cancer
Expert Opin Drug Discov, 1-13 (in press)
DOI 10.1080/17460441.2021.1883585, PubMed 33543671
High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
Mol Oncol, 15 (2), 429-461
DOI 10.1002/1878-0261.12850, PubMed 33176066
MMADHC premature termination codons in the pathogenesis of cobalamin D disorder: Potential of translational readthrough reconstitution
Mol Genet Metab Rep, 26, 100710
DOI 10.1016/j.ymgmr.2021.100710, PubMed 33552904
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
Int J Pharm, 597, 120217 (in press)
DOI 10.1016/j.ijpharm.2021.120217, PubMed 33486035